C

    CytomX Therapeutics Inc (CTMX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.36
    +0.15 (+4.67%)

    Market Cap: $699.46M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    -0.53%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.07
    Range$-0.11 - $0.03
    7 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.11-55.6%
    60d ago$-0.11-48.6%
    30d ago$-0.11-48.6%
    7d ago$-0.11-48.6%
    Current$-0.07
    Revenue Consensus
    $10M
    Range$2M - $37M
    6 analysts
    Dec 31, 2026
    EPS Consensus$-0.10
    Range$-0.23 - $0.01
    7 analysts
    Revenue Consensus
    $-2443120
    Range$-17216050 - $26M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.07---
    Jun 26
    		$-0.09$-0.11+18.18%Beat-7400.0%
    Mar 26
    		$-0.10$-0.11+9.09%Beat-137.0%
    Dec 25
    		$-0.22$-0.09-134.79%Miss-195.7%
    Sep 25
    		$-0.09$-0.04-125.00%Miss-228.6%
    Jun 25
    		$-0.00N/A+98.00%Beat+98.5%
    Mar 25
    		$0.27$0.13+104.24%Beat+58.8%
    Dec 24
    		$0.23$-0.11+309.09%Beat+2200.0%
    Sep 24
    		$0.07$-0.13+153.85%Beat+75.0%
    Jun 24
    		$-0.08$-0.06-33.33%Miss-300.0%
    Mar 24
    		$0.17$-0.06+383.33%Beat+440.0%
    Dec 23
    		$0.01N/A+133.33%Beat+102.3%
    Sep 23
    		$0.04N/A+119.05%Beat+111.4%
    Jun 23
    		$-0.02N/A+90.00%Beat+94.6%
    Mar 23
    		$-0.05N/A+54.55%Beat+86.5%
    Dec 22
    		$-0.43$-0.24-79.17%Miss-7.5%
    Sep 22
    		$-0.35$-0.33-6.06%Miss+0.0%
    Jun 22
    		$-0.37$-0.40+7.50%Beat-23.3%
    Mar 22
    		$-0.37$-0.36-2.78%Miss-42.3%
    Dec 21
    		$-0.40$-0.28-42.86%Miss-25.0%
    Sep 21
    		$-0.35$-0.30-16.67%Miss-9.4%
    Jun 21
    		$-0.30$-0.31+3.23%Beat+11.8%
    Mar 21
    		$-0.26$-0.35+25.71%Beat-200.0%
    Dec 20
    		$-0.32$-0.50+36.00%Beat+59.0%
    Sep 20
    		$-0.32$-0.49+34.69%Beat+38.5%
    Jun 20
    		$-0.34$0.03-1233.33%Miss+46.9%
    Mar 20
    		$0.26$-0.51+150.98%Beat+183.9%
    Dec 19
    		$-0.78$-0.47-65.96%Miss-8.3%
    Sep 19
    		$-0.52$-0.46-13.04%Miss+1.9%
    Jun 19
    		$-0.64$-0.59-8.47%Miss-82.9%
    Mar 19
    		$-0.31$-0.52+40.38%Beat+22.5%
    Dec 18
    		$-0.72$-0.48-50.00%Miss-2500.0%
    Sep 18
    		$-0.53$-0.41-29.27%Miss-89.3%
    Jun 18
    		$-0.35$-0.42+16.67%Beat+49.3%
    Mar 18
    		$-0.40$-0.56+28.57%Beat-73.9%
    Dec 17
    		$0.03N/A+106.52%Beat+107.7%
    Sep 17
    		$-0.28$-0.22-27.27%Miss+30.0%
    Jun 17
    		$-0.69$-0.33-109.09%Miss-
    Mar 17
    		$-0.23N/A+54.90%Beat-
    Dec 16
    		$-0.39$-0.42+7.14%Beat-
    Sep 16
    		$-0.40$-0.31-29.03%Miss-

    Key Metrics

    Valuation
    P/E Ratio-6.72EV/EBITDA24.67x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-1677.00%
    ROE-37.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio9.36xQuick Ratio9.36x
    Trading Statistics
    Beta2.14Avg Volume2.54M
    52-Week High$8.2152-Week Low$1.90

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.35
    SMA 20$3.38
    SMA 50$3.44
    SMA 200$4.16
    EMA 10$3.34
    EMA 20$3.36
    EMA 50$3.44
    EMA 200$3.65

    MACD

    Line: -0.02Signal: -0.02Hist: -0.00

    ADX

    ADX: 9.4+DI: 19.7-DI: 21.7

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down20.0
    PSAR$3.51

    Bollinger Bands

    Upper Band$3.55
    Lower Band$3.21
    %B Position997%(Upper)
    Band Width0.45

    RSI (14-Day)

    Neutral
    49.5

    Momentum Oscillators

    Stoch %K36.7
    Stoch %D38.6
    Williams %R-55.8
    ROC (10d)-2.6%
    Momentum-0.09
    CCI (20d)-88.7
    MFI (14d)50.3

    Volatility Measures

    ATR (14d)$0.18(5.2%)
    StdDev (20d)0.08
    Hist Vol54.4%(High)

    Volume Flow

    VWAP$3.30
    OBV255.9M
    AD Line-26.6M
    CMF (20d)0.096

    Volume Metrics

    Avg Vol (20d)2.5M
    Vol Ratio1.0x
    VWMA (20d)$3.38

    Pivot Points

    R3$3.56
    R2$3.49
    R1$3.35
    Pivot Point$3.28
    S1$3.14
    S2$3.07
    S3$2.93

    Advanced Oscillators

    TSI-4.12
    Ultimate Osc46.1
    KST-26.25

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.42M$10.26M$663,000$5.96M$18.66M$50.92M$38.09M$33.43M$25.11M$41.46M$26.61M$26.38M
    Cost of Revenue$0$0$510,000$0$0$0$413,000$0$0$0$486,000$0
    Gross Profit$1.42M$10.26M$663,000$5.96M$18.66M$50.92M$38.09M$33.43M$25.11M$41.46M$26.61M$26.38M
    Operating Expenses$25.20M$29.93M$28.59M$21.73M$19.94M$28.30M$20.41M$29.32M$33.57M$29.81M$27.21M$23.26M
    R&D$17.60M$19.24M$21.23M$15.30M$13.32M$18.87M$14.79M$21.37M$25.17M$22.05M$19.39M$16.45M
    SG&A$7.60M$10.69M$7.36M$6.43M$6.62M$9.43M$5.62M$7.95M$8.39M$7.75M$7.83M$6.81M
    Operating Income$-23,781,000$-19,672,000$-27,931,000$-15,768,000$-1,286,000$22.62M$17.68M$4.11M$-8,452,000$11.66M$-606,000$3.12M
    Interest Income$3.16M$1.49M$1.48M$1.59M$1.18M$955,000$1.28M$1.69M$1.97M$2.19M$2.50M$2.70M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-20,606,000$-18,189,000$-26,455,000$-14,171,000$-91,000$23.59M$18.94M$5.80M$-6,483,000$13.84M$1.91M$5.82M
    Income Tax Expense$60,000$59,000$55,000$58,000$63,000$62,000$63,000$61,000$51,000$49,000$1.07M$2.82M
    Net Income$-20,666,000$-18,248,000$-26,510,000$-14,229,000$-154,000$23.52M$18.88M$5.74M$-6,534,000$13.79M$837,000$2.99M
    EBITDA$-25,144,000$-20,154,000$-28,145,000$-16,265,000$-1,319,000$22.56M$17.29M$3.31M$-9,433,000$10.25M$-2,337,000$1.67M
    EBIT$-23,763,000$-19,679,000$-27,936,000$-15,763,000$-1,269,000$22.63M$17.66M$4.10M$-8,454,000$11.65M$-597,000$3.12M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CTMX

    News

    CytomX Therapeutics (NASDAQ:CTMX) Downgraded to "Hold" Rating by Zacks Research

    Zacks Research has downgraded CytomX Therapeutics (NASDAQ:CTMX) from a "strong buy" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with a target price of $11.90. This downgrade follows the company's recent miss on quarterly earnings expectations, reporting a loss of $0.09 per share and significantly lower revenue than anticipated. Despite this, institutional investors have increased their holdings in the company, collectively owning 67.77% of the stock.

    MarketBeat•8/21/26•
    Somewhat-Bearish

    CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by Wall Street Zen

    Wall Street Zen has upgraded CytomX Therapeutics (NASDAQ:CTMX) stock rating from "sell" to "hold," though the overall analyst consensus remains a "Buy" with an average price target of $11.90. The company reported a quarterly loss of $0.09 per share and revenue of $1.42 million, both falling short of analyst expectations. Despite this, institutional investors hold 67.77% of the stock, and other analysts have recently issued "outperform" or "buy" ratings with various price targets.

    MarketBeat•8/15/26•
    Somewhat-Bullish

    Point72’s 3.6% CytomX Therapeutics (CTMX) stake detailed in amended filing

    Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have reported an amended passive ownership of 3.6% in CytomX Therapeutics, Inc. (CTMX) common stock, totaling 7,811,033 shares as of June 30, 2026. This stake is held indirectly through an investment fund managed by Point72 Asset Management, with no shares directly owned by the reporting persons. The filing, a Schedule 13G/A, indicates that their beneficial ownership is now at or below five percent of the class.

    Stock Titan•8/14/26•
    Neutral

    Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A

    Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has reported a beneficial ownership of 9.96% in CytomX Therapeutics (CTMX). This group collectively holds shared voting and dispositive power over 21,703,093 shares of common stock. The disclosure was made via a Schedule 13G/A filing, indicating a passive investment intent.

    Stock Titan•8/14/26•
    Neutral

    CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co.

    JPMorgan Chase & Co. has lowered its price target for CytomX Therapeutics (NASDAQ:CTMX) from $12.00 to $11.00, while maintaining an "overweight" rating. This new target suggests a potential upside of 227.19% from the stock's previous close. The adjustment follows CytomX Therapeutics' recent quarterly report, where the company missed earnings and revenue estimates.

    MarketBeat•8/13/26•
    Somewhat-Bearish

    Frequently Asked Questions About CTMX

    Does CTMX pay dividends?
    CytomX Therapeutics Inc (CTMX) does not currently pay a regular dividend.
    What is CTMX's market cap?
    CytomX Therapeutics Inc (CTMX) has a market capitalization of $699.46M with a current stock price of $3.36.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In